United Therapeutics Corporation (UTHR)
United Therapeutics Corporation Book Value per Share: 19.11
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
UTHR Book Value per Share Rankings
| Overall | 78th percentile | 932 of 4380 |
| Sector | 89th percentile | 53 of 505 in Healthcare |
| Industry | 94th percentile | 2 of 39 in Drug Manufacturers - Other |
UTHR Book Value per Share Range, Past 5 Years
| Minimum | 4.306 | Jun 2007 |
| Maximum | 19.11 | Mar 2012 |
| Average | 12.21 |
About Book Value per Share
Book value per share indicates the book value (or accounting value) of each share of stock. Book value is a company's net asset value, which is calculated by total assets minus intangible assets and liabilities. A relatively high book value per share in relation to stock price often occurs when a stock is undervalued.
In the rare circumstance that market price falls below the book value per share, generally a stock is undervalued and might be an attractive buy.
Learn More
You may also be interested in these UTHR related companies
UTHR News
$UTHR Mentioned more than normal on StockTwits - Currently at 9 x average daily social activity
about 30 days ago by TradeIdeasQuant
about 30 days ago by TradeIdeasQuant
I have already accepted my losses for the day...still in half $WFM and half $UTHR. DO NOT FIGHT TO GET BACK YOUR LOSSES EVER. ACCEPT
about 30 days ago by hedgefundhell
about 30 days ago by hedgefundhell
$UTHR Ready to sprint higher and fill the gap from 8/23 $CALL http://chart.ly/je9flbf
about 33 days ago by biostock
about 33 days ago by biostock
United Therapeutics' CEO Discusses Q1 2012 Results - Earnings Call Transcript
Apr 26, 7:40PM Seeking Alpha
Apr 26, 7:40PM Seeking Alpha
United Therapeutics Corporation Reports First Quarter 2012 Financial Results
Apr 26, 6:00AM PR Newswire
Apr 26, 6:00AM PR Newswire
Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest ROE
Apr 24, 3:44AM Benzinga
Apr 24, 3:44AM Benzinga
$UTHR downward trend looks exhausted, time to pounce http://stks.co/3MSK
about 47 days ago by TrendExhaustion
about 47 days ago by TrendExhaustion
Leerink Swann Downgrades United Therapeutics Corp. (UTHR) to Market Perform; Generic Risk
Apr 12, 7:43AM Street Insider
Apr 12, 7:43AM Street Insider
Stocks moving in and out of #MagicFormulaInvesting this week include $ORCL, $UTHR, $TRW and others http://stks.co/3AT2
about 62 days ago by MagicDiligence
about 62 days ago by MagicDiligence
$UTHR files a patent infringement lawsuit against $NVS unit over patents related to a pulmonary hypertension drug.
about 79 days ago by MilionCapital
about 79 days ago by MilionCapital
United Therapeutics Files Lawsuit Against Sandoz for Infringement of Remodulin Patents
Mar 15, 7:02AM Benzinga
Mar 15, 7:02AM Benzinga
New #MagicFormulaInvesting stock United Therapeutics $UTHR. Small pharma firm. Good rev growth, solid bal sheet. One to look at closer.
about 86 days ago by MagicDiligence
about 86 days ago by MagicDiligence
United Therapeutics (UTHR) Reports FDA Accepts NDA for Oral Treprostinil
Feb 21, 7:13AM Street Insider
Feb 21, 7:13AM Street Insider
Brean Murray Carret & Co. Maintains United Therapeutics at Buy, Raises PT from $55 to $57
Feb 14, 11:39AM Benzinga
Feb 14, 11:39AM Benzinga
United Therapeutics' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Feb 14, 11:38AM Seeking Alpha
Feb 14, 11:38AM Seeking Alpha
Collins Stewart: United Therapeutics Reiterates FY12/FY13 Revenue Guidance, Despite 4Q11 Miss
Feb 14, 8:57AM Benzinga
Feb 14, 8:57AM Benzinga
United Therapeutics Corp (UTHR) Reports Q4 EPS of $0.79, Reaffirms FY12, FY13 Guidance
Feb 14, 7:02AM Street Insider
Feb 14, 7:02AM Street Insider
United Therapeutics Corporation Reports 2011 Fourth Quarter and Annual Financial Results
Feb 14, 7:00AM PR Newswire
Feb 14, 7:00AM PR Newswire
$UTHR Insider Sale: $3.6M of stock sold by Paul Mahon (Evp & General Counsel) on February 2, 2012 http://stks.co/2IHV
about 115 days ago by MarketBrief
about 115 days ago by MarketBrief
United Therapeutics (UTHR) Lower As Analyst Highlights Sandoz Generic Remodulin Filing
Feb 07, 10:38AM Street Insider
Feb 07, 10:38AM Street Insider
$UTHR Insider Sale: $3.6M of stock sold by Paul Mahon (Evp & General Counsel) on February 2, 2012 http://stks.co/2GtL
about 116 days ago by MarketBrief
about 116 days ago by MarketBrief
$UTHR http://stks.co/2BCw UTHR is knocking at the door. Long on a good volume break over 50 bucks.
about 122 days ago by gig777
about 122 days ago by gig777
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| UTHR | 43.01 | -1.23 | -2.78% | 2.373B |
| UTG | 25.75 | -0.05 | -0.19% | |
| UTEK | 29.07 | -1.25 | -4.12% | 791.66M |
| UTA | 3.96 | +0.00 | +0.00% | 78.80M |
| USU | 0.7299 | +0.01 | +1.07% | 88.16M |
| USTR | 25.01 | -0.24 | -0.95% | 1.069B |
| USHS | 8.07 | -0.50 | -5.83% | 62.13M |
| USG | 13.96 | -1.46 | -9.47% | 1.624B |
| USEG | 2.22 | -0.03 | -1.33% | 61.76M |
| USD | 31.35 | -2.27 | -6.75% |